Physician profile
Ramiro Coro
NPI 1851320790
$1,517.30
in general payments reported to CMS, 2019-2025
20 companies · $162 in 2025
The $162 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $204 · 2021: $136 · 2022: $111 · 2023: $127 · 2024: $51.68 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $350.21 | 2019-2025 | Airsupra |
| Glaxosmithkline, LLC. | $271.07 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.59 | 2019-2024 | Xifaxan, Trulance |
| Amgen INC. | $115.13 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $81.06 | 2019-2021 | |
| Pfizer INC. | $62.49 | 2019-2022 | |
| Mannkind Corporation | $59.40 | 2022 | |
| Abbvie INC. | $52.90 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $50.89 | 2020-2025 | Zoryve |
| Amarin Pharma, INC. | $50.26 | 2019 | |
| Allergan, INC. | $43.83 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $43.52 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.67 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $27.42 | 2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $26.74 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $22.03 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.97 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.45 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramiro Coro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.